Oncology Venture A/S logo

OV TO 2 - Oncology Venture A/S Share Price

SEK0.172 -0.0  -7.5%

Last Trade - 5:00pm

Sector
Healthcare
Size
Micro Cap
Market Cap £15.8m
Enterprise Value £17.5m
Revenue £96.6k
Position in Universe 1262nd / 1735
Bullish
Bearish
Unlock OV TO 2 Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Oncology Venture A/S revenues decreased 63% to DKR801K. Net loss increased from DKR15.5M to DKR138.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Financial expenses increase from DKR3.4M to DKR30.1M (expense), Other external expenses increase of 40% to DKR46.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

OV TO 2 Revenue Unlock OV TO 2 Revenue

Net Income

OV TO 2 Net Income Unlock OV TO 2 Revenue

Normalised EPS

OV TO 2 Normalised EPS Unlock OV TO 2 Revenue

PE Ratio Range

OV TO 2 PE Ratio Range Unlock OV TO 2 Revenue

Dividend Yield Range

OV TO 2 Dividend Yield Range Unlock OV TO 2 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
OV TO 2 EPS Forecasts Unlock OV TO 2 Revenue
Profile Summary

Oncology Venture A/S, formerly known as Medical Prognosis Institute A/S, is a Denmark-based company engaged in the development of anticancer medicines. It is primarily focused on the tool development for identification of patients with the highest probability of responding to a particular drug candidate, which increases the chance that the drug candidate is to be successful in clinical trials. The Company aims to improve the response rate of anticancer medicines whose clinical development has been suspended. After the clinical trials, the Company is to out-license or sell the drug candidates with a high response rate. The Company’s main drug candidates are comprised of APO010, Irofulven and LiPlaCis.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated September 9, 2004
Public Since October 4, 2013
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm (Dual Listing)
Shares in Issue 121,336,079
Free Float (0.0%)
Eligible for
ISAs
SIPPs
OV TO 2 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for OV TO 2
Upcoming Events for OV TO 2
Frequently Asked Questions for Oncology Venture A/S
What is the Oncology Venture A/S share price?

As of 5:00pm, shares in Oncology Venture A/S are trading at SEK0.172, giving the company a market capitalisation of £15.8m. This share price information is delayed by 15 minutes.

How has the Oncology Venture A/S share price performed this year?

Shares in Oncology Venture A/S are currently trading at SEK0.172 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Oncology Venture A/S price has moved by % over the past year.

What are the analyst and broker recommendations for Oncology Venture A/S?

There are no analysts currently covering Oncology Venture A/S.

When will Oncology Venture A/S next release its financial results?

Oncology Venture A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Oncology Venture A/S dividend yield?

Oncology Venture A/S does not currently pay a dividend.

Does Oncology Venture A/S pay a dividend?

Oncology Venture A/S does not currently pay a dividend.

When does Oncology Venture A/S next pay dividends?

Oncology Venture A/S does not currently pay a dividend.

How do I buy Oncology Venture A/S shares?

To buy shares in Oncology Venture A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Oncology Venture A/S?

Shares in Oncology Venture A/S are currently trading at SEK0.172, giving the company a market capitalisation of £15.8m.

Where are Oncology Venture A/S shares listed? Where are Oncology Venture A/S shares listed?

Here are the trading details for Oncology Venture A/S:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: OV TO 2
What kind of share is Oncology Venture A/S?

Based on an overall assessment of its quality, value and momentum, Oncology Venture A/S is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Oncology Venture A/S share price forecast 2020?

We were not able to load any forecast data for Oncology Venture A/S.

How can I tell whether the Oncology Venture A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncology Venture A/S. Over the past six months, the relative strength of its shares against the market has been %. At the current price of SEK0.172, shares in Oncology Venture A/S are trading at -38.07% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Oncology Venture A/S PE Ratio?

We were not able to find PE ratio data for Oncology Venture A/S.

Who are the key directors of Oncology Venture A/S?

Oncology Venture A/S's management team is headed by:

Duncan Moore - CHM
Frank Knudsen - VCH
Steen Knudsen - CSO
Claus Deichgraeber - VPR
Thomas Jensen - CTO
James Cullem - VBD
Magnus Persson - IND
Rodolfo De Leon - OTH
Ulla Hald Buhl - DIR
Carani Sanjeevi - IND
Steve Carchedi - CEO
Henrik Moltke - CFO
Who are the major shareholders of Oncology Venture A/S?

Here are the top five shareholders of Oncology Venture A/S based on the size of their shareholding:

Similar to OV TO 2
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.